---
title: "Gilead Sciences, Inc. (GILD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GILD.US.md"
symbol: "GILD.US"
name: "Gilead Sciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:45:03.416Z"
locales:
  - [en](https://longbridge.com/en/quote/GILD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GILD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GILD.US.md)
---

# Gilead Sciences, Inc. (GILD.US)

## Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.gilead.com](https://www.gilead.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.41)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 66 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.48% |  |
| Net Profit YoY | 54.50% |  |
| P/B Ratio | 6.85 |  |
| Dividend Ratio | 2.46% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 160994365561.58 |  |
| Revenue | 29736000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 43.19% | A |
| Profit Margin | 30.99% | A |
| Gross Margin | 79.24% | A |
| Revenue YoY | 3.48% | C |
| Net Profit YoY | 54.50% | B |
| Total Assets YoY | -0.28% | D |
| Net Assets YoY | 22.82% | A |
| Cash Flow Margin | 117.25% | C |
| OCF YoY | 3.48% | C |
| Turnover | 0.53 | C |
| Gearing Ratio | 58.37% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Gilead Sciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.48%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "54.50%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.85",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.46%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "160994365561.58",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "29736000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "43.19%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "30.99%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "79.24%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "3.48%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "54.50%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.28%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "22.82%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "117.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "3.48%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.37%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.47 | 34/386 | 23.04 | 21.82 | 19.08 |
| PB | 6.85 | 367/386 | 7.63 | 7.24 | 7.06 |
| PS (TTM) | 5.41 | 114/386 | 5.83 | 5.19 | 4.84 |
| Dividend Yield | 2.46% | 6/386 | 2.79% | 2.59% | 2.31% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **32**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 18 | 56% |
| Overweight | 5 | 16% |
| Hold | 8 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 130.50 |
| Highest Target | 180.00 |
| Lowest Target | 123.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GILD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GILD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GILD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GILD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**